Primary human aorta-derived VSMC (Lonza, Breda, NL) were cultured on gelatin-coated plates at 37°C/5% CO 2 in SmGM-2 medium Objective-In cardiovascular regulation, heme oxygenase-1 (HO-1) activity has been shown to inhibit vascular smooth muscle cell (VSMC) proliferation by promoting cell cycle arrest at the G1/S phase. However, the effect of HO-1 on VSMC migration remains unclear. We aim to elucidate the mechanism by which HO-1 regulates PDGFBB-induced VSMC migration. Methods and Results-Transduction of HO-1 cDNA adenoviral vector severely impeded human VSMC migration in a scratch, transmembrane, and directional migration assay in response to PDGFBB stimulation. Similarly, HO-1 overexpression in the remodeling process during murine retinal vasculature development attenuated VSMC coverage over the major arterial branches as compared with sham vector-transduced eyes. HO-1 expression in VSMCs significantly upregulated VEGFA and VEGFR2 expression, which subsequently promoted the formation of inactive PDGFR/VEGFR2 complexes. This compromised PDGFR phosphorylation and impeded the downstream cascade of FAK-p38 signaling. siRNA-mediated silencing of VEGFA or VEGFR2 could reverse the inhibitory effect of HO-1 on VSMC migration. Conclusion-These findings identify a potent antimigratory function of HO-1 in VSMCs, a mechanism that involves VEGFA and VEGFR2 upregulation, followed by assembly of inactive VEGFR2/PDGFR complexes that attenuates effective PDGFR signaling. (Arterioscler Thromb Vasc Biol . 2012;32:1289-1298 .)
H eme oxygenase-1 (HO-1) exerts a vascular protective function under physiological conditions and disease. Low basic levels of HO-1 in, for example, endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), are significantly upregulated after exposure to its substrate heme and various forms of physical and chemical stress. Heme degradation by HO-1 generates bioactive products that affect the vascular system, including iron, biliverdin, bilirubin, and carbon monoxide (CO). [1] [2] [3] [4] In ECs, the protective function of HO-1 is well studied; HO-1 activation has been shown to be required for both tube formation and directional migration of ECs, a process that is attributed to the bioactive function of CO. 5 In cardiovascular disease, correlation studies in patients with atherosclerosis and knockout studies in murine atherosclerosis models have shown that HO-1 inhibits plaque growth. 4, [6] [7] [8] More importantly, HO-1 is a crucial factor for preventing destabilization of advanced atherosclerotic lesions into (rupture) vulnerable plaques by suppressing immune activation. 9 These studies identify HO-1 as a potent atheroprotective enzyme.
In VSMCs, the HO-1 products, CO and bilirubin, have been implicated to inhibit cell proliferation by promoting cell cycle arrest at the G1/S phase. 10, 11 However, the role of HO-1 in VSMC PDGFBB-induced migration remains to be further elucidated. We demonstrate that HO-1 impedes PDGF-induced VSMC migration by promoting the formation of inactive VEGFR2/PDGFR heterodimer complexes that attenuate PDGFR downstream signaling. We report a novel mechanism by which HO-1 regulates VSMCs activity.
supplemented with a commercial bullet kit, 10% FCS, and penicillin/ streptomycin (Lonza) . Only cell cultures of passages 3 to 6 were used in the experiments.
adenoviral Vector-Mediated Gene transfer and targeted sirNa Knockdown in Cell Culture
The commercial pAd/CMV/V5 Gateway system (Invitrogen, Breda, NL) was used to generate recombinant adenoviral vectors according to the manufacturer's recommendations. Viral particles were harvested from 293 cell lysates. and the viral titer was determined by viral plaque assays. ∆E1/E3-sham adenovirus was used as a control adenovirus (adsham) in all studies. Primary human VSMCs were transduced by adHO1 or adsham (MOI 100) in SmGM-2 basal medium in serum low conditions (2% FCS, Lonza) for 2 hours. Additional targeted knockdown of VEGFR2 was achieved by transfer of a mix of 4 specific siRNAs sequences directed against VEGFR2 mRNA (Smartpool, Dharmacon, Etterleur, NL) in 50% to 60% subconfluent VSMC cultures, at 24 hours before adHO1 or adsham transfection. As control, cells were transfected with a mix of 4 scrambled, nontargeting siRNAs (Dharmacon). Overexpression of the HO-1 was verified by quantitative (q)PCR and Western blot analysis at 1 and 2 days after adenoviral transduction, respectively. Efficient silencing of VEGFR2 was assessed by qPCR analysis at 3 days after transfection.
A detailed description of the rest of the methods can be found in the online Data Supplement.
results

HO-1 inhibits directional Migration of VsMCs under PdGFBB stimulation
We examined the effect of HO-1 overexpression on PDGFmediated migration of human aorta-derived VSMCs. Adenoviral vector-mediated transduction of human HO-1 resulted in a significant increase in HO-1 mRNA and protein levels, as validated by qPCR and Western blot analysis as compared with sham adenovirus-transduced VSMCs at 48 and 72 hours, respectively ( Figure 1A and 1B). To exclude any confounding effect of cell proliferation, the data of the migration assays were acquired after 4 hours of VSMC migration. In a standard scratch assay, HO-1 expression reduced the migratory distance in response to 10 ng/nL PDGFBB by 62% ( Figure 1C ). To assess the effect of HO-1 on VSMCs during injury-independent migration, a transwell migration assay was also conducted. HO-1 overexpression attenuated PDGFBB-induced transwell-movement of VSMCs by 43%, as compared with sham virus-treated cells ( Figure 1D ). Likewise, in a directional-migration assay, HO-1 expression in VSMCs decreased the absolute migration distance by 34% as compared with sham-transduced VSMCs ( Figure 1E ). The absolute migration distance is the distance that each tracked VSMC has migrated from its starting point to its end point during 2 hours of chemotactic migration in response to PDGFBB. Decrease in VSMC migration after HO-1 overexpression was associated with loss of cell polarity, which is required for directional migration. 13 HO-1 significantly reduced polarization of the microtubuli-organizing center (MTOC) toward the direction of the cell-clear area, as shown by g-tubulin staining of the MTOC and acetylated a-tubulin staining of the microtubule cytoskeleton ( Figure 1F ). As previously reported, HO-1 inhibits cell cycle progression in VSMCs via a p21 cip1 -dependent pathway. 4 To distinguish between the effect of HO-1 on migration and cell proliferation, we conducted experiments in mitomycin-c-treated VSMCs in which cell cycle progression was blocked in the early prophase. HO-1-induced inhibition in VSMC migration was independent from the gene's effect on cell proliferation, as a decrease in VSMC migration was observed in the mitomycin-c-treated cultures in response to PDGFBB ( Figure 2A ) or VEGFA stimulation ( Figure 2B ).
To identify the effective HO-1 metabolite in VSMC-migration repression, directional migration response to PDGFBB was assessed during coincubation with 50 M and 100 M of bilirubin or CO using the potent CO donor tricarbonyldichlororuthenium (II) dimer (CO-releasing molecule [CORM2]). Bilirubin did not affect VSMC migration ( Figure 2C and Figure 
HO-1 decreases VsMC Migration during Postnatal arterial differentiation of the retinal Vasculature in Mice
Next, we validated the inhibitory effects of HO-1 in vivo. During the postnatal retinal vasculature development in mice, mural cells including VSMCs and pericytes migrate over the major blood vessels of the vascular tree that are destined to become arteries. Intravitreal injection of adenovirus with a vector encoding the full-length murine HO-1 cDNA at day 4 induced significant upregulation of HO-1 mRNA as compared with sham virus-injected controls ( Figure 3A ). HO-1 expression did not affect the progression of the vasculature toward the retinal borders, as indicated by isolectin-B4 staining of endothelial cells. To assess VSMC migration in vivo, the length of the VSMC-covered arteries was divided by the total distance between neural plexus and the retinal borders to calculate relative length (X=[A/B]*100) ( Figure II in the online-only Data Supplement). HO-1 reduced the relative length of the VSMC-covered arteries (% distance in X) that originated from the optical disk, as shown by VSMC a-actin staining: HO-1 adenovirus-transduced retinas showed a 35% decrease in the relative length of the VSMC covered arteries as compared with sham virus-transduced controls ( Figure  3B ). To validate that vascular expansion is not affected by HO-1, the length of the vascular network was divided by the total distance between neural plexus and the retinal borders to calculate relative length, using isolectin-B4 staining (for ECs, Y=[A/B]*100). The relative length (% distance Y) of the vascular network was not affected by HO-1 overexpression as compared with adsham-transduced controls.
Moreover, in normal retinal development, the proximal section of the side branches of the major retinal arteries are covered by VSMCs. HO-1 expression significantly reduced VSMC coverage of these side branches at junctional sites ( Figure 3C ), whereas the EC vessel density was not affected. To further validate these findings, Western blot analysis of the endothelial marker CD31 and VSMC marker VSMC a-actin was performed. In line with the whole mount analysis, retinal protein levels of CD31 were not affected by HO-1 overexpression, whereas a significant increase in VSMC a-actin level was observed as compared with adsham-injected mice ( Figure 3D ). Assessment of -actin showed no difference in loading/blotting efficiency. These data demonstrate that in the murine retinal vascular development model, HO-1 overexpression mainly affects VSMCs.
HO-1 attenuates PdGFrb signaling by Promoting VeGFr2/PdGFrb Complex Formation
To test whether the decline in migration efficiency in response to HO-1 could be attributed to poor PDGFR chemotactic signaling, we assessed PDGFR phosphorylation in primary human VSMCs in response to PDGFBB stimulation in vitro. Western blot analysis shows that PDGFBB stimulates PDGFR phosphorylation at the activation site Tyr1021 in sham-transduced VSMC cultures, whereas HO-1 overexpression diminishes the PDGFBB-induced response ( Figure 4A ). Immunoblotting for -actin showed no differences between the 2 groups. PDGFR deactivation was associated with a significant upregulation in VEGFA and VEGFR2 mRNA levels in HO-1-expressing cells, as demonstrated by qPCR ( Figure 4B ). PDGFBB/VEGFA stimulation resulted in VEGFR2/PDGFR complex formation in primary human VSMCs, as detected by coimmunoprecipitation (co-IPP) ( Figure 4C ). HO-1 expression in VSMCs significantly increased VEGFR2 binding to PDGFR ( Figure 4C ), indicating that HO-1 promotes the formation of the inactive VEGFR2/PDGFR complex. We validated these findings by conducting the Co-IPP with a VEGFR2-pulldown followed by PDGFR immunoblotting (Figure 4D ). In line with our qPCR findings, HO-1 overexpression in VSMCs increased VEGFR2 protein levels, resulting in more capture of VEGFR2 protein on the Co-IPP beads ( Figure 4D and 4E ). VEGFR2/ PDGFR complex formation could be confirmed in both adsham-treated and adHO-1-treated samples. Quantification of the Co-IPP PDGFR/VEGFR2 ratio showed no difference, due to an increase in VEGFR2 levels as a result of HO-1 expression ( Figure 4E ). However, a significantly higher level of PDGFR phosphorylation was detected in the PDGFR/ VEGFR2 complexes formed in the adHO-1-treated group, as indicated by an increase in phospho-PDGFR/PDGFR ratio in the adHO-1 Co-IPP samples versus the Co-IPP adsham samples ( Figure 4E ). These data clearly indicate that PDGFR/VEGFR2 complex formation is indeed increased in response to HO-1 expression.
Western blot analysis of whole lysates further showed that HO-1 prevented PDGFBB-induced FAK Y397-phosphorylation ( Figure 5A ). In line with a decline in PDGFR signaling, HO-1 overexpression in VSMCs decreased p38 phosphorylation as compared with sham-treated VSMCs (Figure 5B ), whereas total p38, total ERK1/2, and The panels show no difference in effective pulldown of PDGFR protein between adsham-and adHO1-treated VSMCs, whereas coimmunoprecipitation (co-IPP) of VEGFR2 was increased in adHO1-transduced VSMCs as compared with adshamtransduced controls. Immunoprecipitation using a mouse IgG isotype control showed no effective pulldown of PDGFR. Bar graph shows VEGFR2 levels in the adsham and adHO1 Co-IPP samples normalized for PDGF pulldown efficiency (VEGFR2 ratio). D, Immunoprecipitation of VEGFR2 in adsham-and adHO1-transduced VSMCs, 30 minutes after VEGFA/PDGFBB costimulation. The micrograph shows a significant difference in effective pulldown of VEGFR2 protein between adsham-and adHO1-treated VSMCs. The second micrograph shows coimmunoprecipitation (co-IPP) of PDGFR, and the lowest micrograph shows coimmunoprecipitation (co-IPP) of phospho-PDGFR. E, Bar graphs show that VEGFR2 immunoprecipitation protein levels in adHO1 Co-IPP samples were significantly increased versus adsham Co-IPP samples. Quantification of the Co-IPP PDGFR/VEGFR2 ratio showed no difference, due to a significant increase in VEGFR2 levels. However, significant increase in phospho-PDGFR/PDGFR ratio in the adHO1 Co-IPP samples versus the Co-IPP adsham samples was observed. Data are presented as mean±SD of 4 separate experiments; *P<0.05 versus adsham. phospho-ERK1/2 protein levels remained unaffected ( Figure  5A through 5C) . Immunoblotting for -actin showed no differences between the 2 groups.
VeGFr2 silencing rescues HO-1-induced antimigratory effects on VsMCs
To validate whether the deleterious effects of HO-1 on VSMC migration is caused by VEGFR2/ PDGFR heterodimer complex formation, VEGFR2 was silenced using siRNA technology in HO-1-expressing VSMCs in a transwell migration assay. Efficient silencing of VEGFR2 was validated by qPCR analysis ( Figure 6A ). Transgenic HO-1 expression in VSMCs inhibited cell migration as compared with nontransduced and sham adenovirus-transduced VSMCs ( Figure 6B ). VSMCs treated with both adHO1 and nontargeting scrambled siRNA (sisham) showed a similar reduction in migration capacity in response to PDGFBB. However, transfection with siRNA targeting VEGFR2 rescued the attenuating effect of HO-1 on VSMC migration. Similarly, in a directional migration assay, the inhibitory effects of HO-1 on VSMCs migration could be reversed by VEGFR2 silencing (Figure 6C ). Likewise, knockdown of VEGFA in HO-1 overexpressing VSMCs attenuated the inhibitory effect of HO-1 on directional migration ( Figure  6D ). Taken together, these data indicate that HO-1 impairs VSMC migration via VEGFA and VEGFR2 regulation. To verify that HO-1 interference of VSMC migration is indeed mediated via p38 MAPK signaling, directional migration assays were conducted with VSMCs that were double-transduced with adHO-1 and a cDNA plasmid that expresses constitutively active MAPKAPK2, a direct downstream target of p38. Indeed, migration of adHO-1 treated VSMCs was successfully rescued by restoration of the p38 signaling cascade ( Figure 6E ). Knockdown efficiency was validated by qPCR analysis and showed ≈66% effective silencing of VEGFA and ≈2-fold induction of MAPKAPK2 as compared with the appropriate controls (sisham-or adsham-treated). These additional studies further provide proof for the involvement of p38 signaling and VEGFA in the observed HO-1-mediated effects on migration.
discussion
This study provides evidence for HO-1-mediated interference of PDGFBB-induced migration of VSMCs, demonstrated in vitro using standard migration assays, and in vivo, using a murine model for retinal vasculature development. The data in the retina model identified HO-1 as a potent regulator of arterial vessel differentiation by modulating VSMC coverage.
Although the effect of HO-1 on VSMC proliferation via modulation of cell cycle progression regulatory proteins such as p21 cip1 and p27 kip1 has been well described, 11, 14 the effect of HO-1 on migration and subsequent regulatory mechanism must be further elucidated. Our studies identified HO-1 as a potent inhibitor of VSMC migration. Previously, Rodriguez et al have shown in in vitro studies that HO-1 could impede VSMC migration via inhibition of Nox1 enzymatic activity. 15 In the current study, we describe a novel molecular mechanism for HO-1 in VSMC regulation, providing first-time evidence that HO-1 impedes VSMC migration by interference of PDGFR signaling via VEGFR2 and VEGFA upregulation. It has been reported that HO-1 could promote tube formation and vessel sprouting in ECs. 16 In the murine postnatal retinal vasculature development model, vascular network expansion occurs during the first 7 days after birth over the retinal surface from the neural plexus site toward the retinal boundaries. 17 The lack of difference at day 8 between adHO1-treated and adsham-treated retinas in relative length of the vasculature indicate that at least in our model, vascular network expansion was not in vivo affected by HO-1 overexpression. In contrast, HO-1 impeded vascular coverage by VSMCs, both shown by reduction in the distance achieved by VSMC migration over the predeveloped vascular structures ( Figure 2B) , and a decrease in the numbers of vessel junctions that are covered by these mural cells ( Figure 2C ) in adHO1-transduced eyes. It was previously demonstrated that PDGFBB and VEGFA costimulation inhibited VSMC coverage of the EC vasculature in a matrigel angiogenesis model in mice, pointing toward an antagonistic relation between PDGF and VEGFA during neovacularization. 18 In our study, HO-1 induced upregulation of VEGFR2 and VEGFA, which coincided with increased formation of inactive VEGFR2/PDGFR heterodimers. Indeed, it has been reported that PDGFBB/VEGFA coactivation could lead to competitive binding of VEGFR2 to PDGFR, resulting in inactive VEGFR2/PDGFR heterodimers. 18 Previous studies reported that HO-1 could enhance VSMC production of VEGFA, 19, 20 whereas HO-1-derived CO release by VSMCs could downregulate PDGFBB production by neighboring endothelial cells. 21 Therefore, HO-1 could induce a shift in VEGFR2 and PDGFR ratio, thereby promoting the formation of these heterodimers. In vitro migration assays comparing CO with bilirubin stimulation indeed show that CO is the main metabolic product of HO-1 involved in the inhibitory effect of the enzyme in line with previous reports of the cytostatic function of CO on VSMC during hypoxia. 22 In our study, HO-1 significantly increased VEGFR2 and VEGFA levels, whereas PDGFR expression remained unaffected (data not shown), indicating that in the case of HO-1 upregulation in VSMCs, the shift in this VEGFR2/PDGFR ratio favoring heterodimer formation was mainly attributed to the rise in VEGFR2 signaling. Further evidence that VEGRF2 and VEGFA upregulation by HO-1 was responsible for its antimigratory function was provided by our additional in vitro migration experiments, which clearly showed that VEGFR2 or VEGFA silencing could rescue the HO-1-induced phenotype in VSMCs, indicating that inhibition of PDGFBB induced VSMC migration by HO-1 is indeed mediated via a VEGFR2/VEGFA-dependent pathway.
We then further hypothesized that HO-1-induced VEGFR2/ PDGFR heterodimer formation would diminish overall PDGF signaling by competing with active PDGFR homodimer formation. Indeed, PDGFR phosphorylation at the Tyr1021 activation site was significantly decreased by HO-1 in VSMCs, whereas total PDGFR remained unaffected. In addition, phosphorylation of PDGFR in the PDGFR/VEGFR2 complex was diminished by HO-1 overexpression. The PDGF signaling cascade further involves binding of the functional PDGFR homodimer complex to FAK, which subsequently triggers FAK activation via phosphorylation of its SH2-binding site Y397 by cSrc family members. 23 Further downstream, PDGFBB signaling triggers activation of the mitogen activated protein (MAP) kinase family members, including ERK1/2 and p38. Whereas ERK1/2 activation is mainly required for cell proliferation, p38 activation is crucial for PDGFBB-induced actin-cytoskeleton reorganization during cell migration. 24 In our experiments, HO-1 expression in VSMCs mainly impeded activation of the FAK-p38 signaling cascade, implying that the earlier reported inhibitory effects of HO-1 on VSMC proliferation is regulated via a PDGFBB independent pathway. It has been demonstrated that the antiproliferative effect of HO-1 on VSMCs was mediated via increased bioavailability of cyclic guanosine monophosphate (cGMP) activation, which subsequently leads to upregulation of p21 CIP . 11 The bioactive product of HO-1 CO converts via activation of soluble guanylyl cyclase, guanosine triphosphate (GTP), into cGMP. 4 Therefore, HO-1 inhibition of VSMC proliferation could be attributed to a rise in intracellular CO levels.
Previously, we have shown that heme oxygenase 1 could inhibit cell cycle progression by inducing G1 cell cycle arrest. 11 This additional function of the gene could complicate the interpretation of the data on migration. To exclude potential off-target effects of HO-1 on VSMC, we acquired the data in the different migration assays within 4 hours of incubation time. Because most primary human cells in culture including VSMCs go through the G1/G2 cell cycle once per 12 hours, it is very unlikely that cell division would have a profound effect on the migration results, as the division time for both the HO-1-silenced group and the controls are close to nonsignificant and therefore comparable. More importantly, live imaging of single cells followed during 2 hours of migration rules out the effect of HO-1 as a confounding factor and clearly shows that HO-1 impeded migration of VSMCs. In addition, migration experiments with the cell cycle inhibitor mitomycin-c have further validated the specific antimigratory function of HO-1.
Our findings imply that increased VEGFR2 activation and subsequent VEGFR2/PDGFR heterodimer formation could be involved in the protective effect of HO-1 overexpression that was previously observed in an animal model of arterial restenosis. 11, 25 Clinical restenosis, as observed in cardiovascular patients, is characterized by VSMC proliferation and migration in response to vascular injury during treatment, leading to pathological neointimal growth and lumen occlusion. New experiments are currently set up to assess the role of HO-1 in PDGFBB-induced migration of VSMCs in this disease.
In conclusion, this study identified HO-1 as an important regulator in the process of VSMC migration and described for the first time a novel molecular mechanism in which HO-1 induces VSMC insensibility to PDGF chemotaxis, by compromising PDGFR signaling via VEGFR2 and VEGFA upregulation.
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